EX-99.1 2 drr0139_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1

 

Dr. Reddy’s Laboratories Ltd.
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500 034, Telangana,
India.
CIN: L85195TG1984PLC004507
   
  Tel     :+91 40 4900 2900
  Fax    :+91 40 4900 2999
  Email :mail@drreddys.com
  www.drreddys.com

 

July 10, 2019

 

Corporate Relationship Department   National Stock Exchange of India Ltd.
BSE Limited   “Exchange Plaza”
Dalal Street, Fort   Bandra-Kurla Complex, Bandra (East),
Mumbai – 400 001   Mumbai – 400 051
Fax Nos.: 022-22723121 / 22723719 /   Fax Nos.: 022-26598120/ 26598237/
  22722037 / 22722039     26598238
         
Scrip Code: 500124   Scrip Code: DRREDDY-EQ

 

Dear Sirs,

 

Sub: Press Release

 

Please find enclosed a Press Release on “Dr. Reddy's to release Q1 FY 20 results on July 29, 2019 Earnings call slated for July 29, 6:30 PM IST / 9:00 AM EDT”

 

This is for your information.

 

With regards,

 

/s/ Sandeep Poddar  
Sandeep Poddar  
Company Secretary  

 

Encl: As above

 

CC:- New York Stock Exchange Inc.(Stock Code :RDY)

 

   

 

  

 

  CONTACT
DR. REDDY'S LABORATORIES LTD. Investor relationS Media relationS
8-2-337, Road No. 3, Banjara Hills,
Hyderabad - 500034. Telangana, India.

AMIT AGARWAL

amita@drreddys.com

(Ph: +91-40-49002135)

MITALI SARKAR

mitali.sarkar@drreddys.com
(Ph: +91-40-49002121)

 

 

 

Dr. Reddy's to release Q1 FY 20 results on July 29, 2019

Earnings call slated for July 29, 6:30 PM IST / 9:00 AM EDT

 

Hyderabad, India, July 10, 2019

 

 

 

Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the first quarter ended June 30, 2019 on Monday, July 29, 2019 after the Board Meeting.

 

Summary of Events

 

Event Date and Time Medium
Release of financial results Jul 29th, after the Board Meeting Email, Media, Company website, Business wire
Press meet presentation Will be available on the Company’s website URL available on Company’s website, www.drreddys.com
Earnings Call Jul 29th, 6:30 PM IST / 9:00 AM EDT

Hosted by the Company

(Details below)

Playback of Earnings Call After the earnings call till August 5th, 2019     Details below
Transcript of the Earnings call Will be available on the Company’s website URL available on Company’s website, www.drreddys.com

 

Earnings Call

 

Following the release, the management of the Company will host an earnings call to discuss the Company’s financial performance. (Dial In and other details given below)

 

Play Back

 

The play back will be available after the earnings call, till August 5th, 2019. For play back dial in phone No: 022 7194 5757 / 022 6663 5757, and Playback Code is 20718.

 

 

   

 

  

Conference Dial-In Numbers

Universal Access Number:

 

+91 22 6280 1219

+91 22 7115 8120

Local Access Number:

Available all over India

+91 70456 71221
International Toll Free Number:

USA: 1 866 746 2133

UK: 0 808 101 1573

Singapore: 800 101 2045

Hong Kong: 800 964 448

 

No password/pin number is necessary to dial in to any of the above numbers. The operator will provide instructions on asking questions before and during the call.

 

 

 

 

About Dr. Reddy’s: Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) is an integrated pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services & Active Ingredients, Global Generics and Proprietary Products – Dr. Reddy’s offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, biosimilars and differentiated formulations. Our major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology. Dr Reddy’s operates in markets across the globe. Our Major markets include – USA, India, Russia & CIS countries, and Europe. For more information, log on to: www.drreddys.com

 

 

 

Disclaimer: This press release may include statements of future expectations and other forward-looking statements that are based on the management’s current views and assumptions and involve known or unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. In addition to statements which are forward-looking by reason of context, the words "may", "will", "should", "expects", "plans", "intends", "anticipates", "believes", "estimates", "predicts", "potential", or "continue" and similar expressions identify forward-looking statements. Actual results, performance or events may differ materially from those in such statements due to without limitation, (i) general economic conditions such as performance of financial markets, credit defaults , currency exchange rates , interest rates , persistency levels and frequency / severity of insured loss events (ii) mortality and morbidity levels and trends, (iii) changing levels of competition and general competitive factors, (iv) changes in laws and regulations and in the policies of central banks and/or governments, (v) the impact of acquisitions or reorganization , including related integration issues.

 

The company assumes no obligation to update any information contained herein.